[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. John's Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100587327","safeboosc-iiiv---does-cerebral-oximetry-monitoring-affect-renal-outcomes-100587327",false,"NCT06926946","SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes","The Effects of Treatment Guided by Cerebral Oximetry Monitoring on Renal Outcomes in Invasively Mechanically Ventilated Neonates: an Ancillary Study of the SafeBoosC-IIIv Trial","SBIIIvR","Inclusion Criteria:\n\n* \\> 28 weeks of gestation Invasively ventilated\n\nExclusion Criteria:\n\n* major anomalies","ALL","1 Day","28 Days",{"count":21,"type":22},1000,"ESTIMATED","INTERVENTIONAL",[25],"NA","Cerebral oximetry monitoring allows clinicians to optimize blood flow to the brain and oxygenation using the SafeBoosC treatment guideline. The guideline's interventions aims to stabilize blood pressure and oxygen levels.\n\nAs low blood pressure is a risk factor for the development of kidney injury, normalizing blood pressure may decrease the incidence of kidney injury in new-borns who are on ventilator.",[28,29],"Acute Renal Failure","Neonatal Morbidity",[31,32,33,34,35],"Cerebral oximetry","NIRS","Neonate","Ventilated","Kidney injury","NOT_YET_RECRUITING","2025-07-17",{"date":39,"type":40},"2025-07-23","ACTUAL",{"date":42,"type":22},"2025-07-31",{"date":44,"type":22},"2027-09-15",{"name":46,"class":47},"St. John's Research Institute","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100580389","impact-cost-and-sustainability-of-a-customized-low-cost-intervention-to-reduce-cardiovascular-disease-burden-in-india-a-cluster-randomized-trial-100580389","NCT06836661","Impact, Cost, and Sustainability of a Customized, Low-Cost Intervention to Reduce Cardiovascular Disease Burden in India: A Cluster Randomized Trial","Effect, Cost, and sustaiNability of a Synergistic, Multipronged, Customized, Low-cost Intervention Package to Reduce cArdiovascular Burden Across India: a cLustEr RCT","ENABLE","Inclusion Criteria:\n\n\\- 1. High-risk primary prevention A. Patients aged more than 40years of any gender without a CVD event (MI, Stroke) with at least two of the following risk factors, A to E with a 10 year documented evidence OF (a to d) a. Diabetes Mellitus b. Hypertension c. Dyslipidaemia d. Microalbuminuria e. Family history of premature CVD event (MI, stroke or CVD-related death under 55 years) B. Patients aged above 50years of any gender without a CVD event (MI, Stroke) with at least one year of documented disease, at least two A to D (Above) 2. High-risk secondary prevention Patients aged above 40 years or above, with a CVD event with any one of the following: options a. MI or stroke less than three months, \\\u003Cbr\u002F\\> b. MI or stroke, more than three months, but less than one year with at least one comorbid condition, that is A to E (Above).\n\nc. Patients aged above 60 years or above with MI or stroke greater than three months BUT less than one year, without any comorbid condition. These patients are expected to have a moderate to high risk of a CVD event or death in the next three years.\n\nExclusion Criteria:\n\n* We will exclude patients with any ONE of the following:\n\n  1. Severe cognitive impairment of any aetiology and have no reliable caregivers.\n  2. Medical conditions with a survival prognosis of less than 12 months.\n  3. Unable to follow-up for the study period","40 Years","99 Years",{"count":60,"type":22},1560,[25],"The ICRAG-2 project aims to assess the impact, cost-effectiveness, and sustainability of a low-cost, multipronged intervention package to reduce cardiovascular disease (CVD) burden in India. Given the high CVD mortality rate in India, this study addresses the urgent need for scalable, evidence-based solutions. The project will unfold in three steps: first, formative research including systematic reviews, cross-sectional studies, and qualitative studies will identify key barriers, facilitators, and refine interventions. Next, a matched-pair cluster randomized controlled trial (CRCT) across 26 clusters will evaluate the intervention's impact on CVD outcomes over three years, focusing on therapeutic lifestyle changes, fixed-dose medications, and task-sharing with non-physician health workers. Finally, the project will engage stakeholders through policy dialogues to support potential national-scale implementation. This trial offers a promising model to reduce CVD incidence through customized, sustainable interventions targeting patients, providers, and the health system.",[64,65],"ST Elevation (STEMI) Myocardial Infarction of Anterior Wall","Cardiovascular Diseases",[67,68,69,70],"CVD","Low cost intervention","task sharing","fixed dose combination pills","2025-05-14",{"date":73,"type":40},"2025-05-18",{"date":75,"type":22},"2025-06-01",{"date":77,"type":22},"2029-06-30",{"name":46,"class":47},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100531577","phase-2-evaluating-a-nitric-oxide-generator-nebivolol-as-a-disease-modifier-in-patients-with-diabetic-neuropathy-100531577","NCT06201611","Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.","A 3-arm, Open-label, Stratified Randomized Controlled Trial With Blinded End-point Assessment to EValuate A Nitric oxidE Generator (Nebivolol) as a diSease Modifying mediCatioN in Diabetic Peripheral Neuropathy","EVANESCENT-DPN","Inclusion Criteria:\n\n1. Patients aged \\>= 18 years diagnosed with diabetes mellitus, of a duration of \\\u003C= 5 years since their diagnosis\n2. HbA1c \\\u003C 9 at enrolment with stable glycemic control for the last three months\n3. Neuropathy meeting the following 'Toronto criteria' (8) - (a) abnormal nerve conduction study\\* based on age-matched controls at the site and - (b) a symptom or sign of neuropathy defined as one of either a diabetic neuropathy symptom score of \\>= 1\u002F4 Or neuropathy disability score of \\>= 3\u002F10 (9).\n\n   * Abnormal NCS defined as one or more abnormal Z score in two or more nerves, based on sural nerve amplitude (antidromic stimulation), tibial and peroneal NCV, tibial amplitude, increased F-wave minimum latency (F-min), and absent F-waves (only considered abnormal in tibial nerve)\n\nExclusion Criteria:\n\n1. Absolute contra-indications for nebivolol - sick-sinus syndrome, sinus bradycardia with a resting heart rate \\\u003C 50\u002F minute, second or third degree AV-nodal blocks fascicular blocks, severe asthma or COPD and acute heart failure\n2. Patients with a compelling indication for a non-dihydropyridine calcium channel blocker (CCB)\n3. Patients with compelling need for another beta-blocker in the judgement of the treating team\n\nPatients who have undergone major amputations of the lower limbs or are posted for the same.","18 Years",{"count":89,"type":22},120,[91,92],"PHASE2","PHASE3","The goal of this clinical trial is to test in patients with diabetic neuropathy,\n\n* Can Nevibolol at a dose of 2.5 mg- 10 mg compared with standard pain modulating treatment conserve the mean nerve action potential amplitude (sural and tibial nerves) at 24 weeks follow- up.\n* Can Nevibolol at a dose of 2.5 mg- 10 mg compared with a combination of Alpha Lipoic Acid (600 mg\u002Fday)+EPALRESTAT (150 mg\u002Fday) conserve the mean nerve action potential amplitude (sural and tibial nerves) at 24 weeks follow- up\n\n  * All potential participants will undergo screening- about 10 ml of blood will be drawn to perform the following assesments at screening- HbA1c, FBS,Vit B12, TSH, fT4.\n  * Baseline assessments conducting a nerve conduction study, quality of life assesment using Eq-5D-5L and NRS pain score.\n  * 20% of patients (24 patients) will undergo Sudoscan, Corneal confocal microscopy and a skin biopsy for assessing IENFD (Intra Epidermal Nerve Fibre Density).\n  * 15th day, 1 month and 3rd month followup for evaluating patients status and medication adherance.\n  * 6th month followup for evaluating patients status and medication adherance.\n\nResearchers will compare Nebivolol against combination of Epalrestat+Alpha Lipoic Acid against standard pain modulating treatment to evaluate their diseaes modifying effect as reflected by nerve conduction study parameters.",[95],"Diabetic Neuropathy Peripheral","RECRUITING","2025-02-01",{"date":99,"type":40},"2025-02-04",{"date":101,"type":40},"2024-11-15",{"date":103,"type":22},"2026-03-30",{"name":46,"class":47},2,""]